Switching from an analogous to a stable isotopically labeled internal standard for the LC‐MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance
- 19 July 2004
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 18 (6) , 400-402
- https://doi.org/10.1002/bmc.392
Abstract
The importance of a stable isotopically labeled (SIL) internal standard for the quantitative LC‐MS/MS assay for Kahalalide F in human plasma is highlighted. Similar results can be expected for other LC‐MS/MS assays. Therefore, we emphasize the need for an SIL internal standard for accurate and precise LC‐MS/MS assays of drugs in biological matrices. Copyright © 2004 John Wiley & Sons, Ltd.Keywords
This publication has 3 references indexed in Scilit:
- Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high‐performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometryJournal of Mass Spectrometry, 2002
- Different quantitation approaches for xenobiotics in human urine samples by liquid chromatography/electrospray tandem mass spectrometryRapid Communications in Mass Spectrometry, 2002
- Mass Spectrometry for Chemists and BiochemistsPublished by Cambridge University Press (CUP) ,1996